A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17011664

Enrollment

Unknown

Registered

2017-06-14

Start date

2017-08-01

Completion date

Unknown

Last updated

2017-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary ACTH-secreting adenoma

Interventions

Treatment group:lapatinib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-75 years old; (2) clinical pathological diagnosis of pituitary ACTH adenoma, and can obtain pathological tissue; (3) the patient agrees to participate in this experiment, and sign informed consent; (4) diagnosed as the refractory pituitary ACTH-secreting adenoma.

Exclusion criteria

Exclusion criteria: (1) do not meet the criteria of refractory pituitary ACTH-secreting adenoma; (2) Incomplete medical records; (3) can not accept follow-up; (4) pregnant or lactating women; (5) using other drugs and / or alcohol abuse (6) serious respiratory depression (lung), airway obstruction; (7); heart disease (i.e., above grade II and grade II cardiac function); (8) blood system diseases; (9) brain disease patients with impaired judging ability.

Design outcomes

Primary

Measure	Time frame
serum ACTH level;	—

Secondary

Measure	Time frame
serum cortisol level;24hour UFC;Size of pituitary adenoma;	—

Countries

China

Contacts

Public ContactRenzhi Wang

Peking Union Medical College Hospital

wangrz@126.com+86 010-69152532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026